Perceptive Informatics is Selected by Almirall to Provide eClinical Solutions for Critical Respiratory Program

Perceptive Informatics is Selected by Almirall to Provide eClinical Solutions for Critical Respiratory Program
Boston, MA, January 14, 2010 -
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), announced today that it has been selected by Almirall, an international pharmaceutical company, to provide core solutions in its eClinical Suite for several clinical trials in the respiratory therapeutic area. Through this relationship, Perceptive is leveraging the core capabilities of its eClinical Suite to support Almirall in gaining greater visibility into its clinical trials and improving data access for faster decision-making.

"Perceptive is pleased to provide Almirall with core technologies in our eClinical Suite to assist in increasing trial efficiency," said Steve Kent, President of Perceptive Informatics. "A key goal is to provide our customers with the most interoperable technology solutions to enable effective information flow across various functions and organizations involved in executing clinical studies."

Almirall is using the DataLabs® EDC (Electronic Data Capture) solution from Perceptive in order to gain a better integrated view of clinical trial data. Almirall also uses other technologies in Perceptive's eClinical Suite, such as the IMPACT® CTMS (Clinical Trial Management System) and the ClinPhone® RTSM (Randomization and Trial Supply Management) technologies, to facilitate several of its clinical trials.

"The eClinical technologies and services provided by Perceptive Informatics have helped us to access data seamlessly, save time, and reach decision points faster about new compounds, which is especially important for the complex clinical trials we conduct in the respiratory therapeutic area. Almirall looks forward to continuing to work to maximize our use of advanced eClinical solutions that can assist us in accelerating the clinical development process, as we maintain a continued focus on innovation and our goals to improve health and well-being," said Estrella Garcia, Ph.D., Head of Global Clinical Operations & Strategic Resourcing, Almirall.
The eClinical Suite from Perceptive Informatics takes integration to the next level and brings about a dramatic shift in the way technologies can be used to simplify workflow while facilitating effective trial management. Providing advanced integration and interoperability among systems, including the IMPACT® CTMS, the DataLabs® EDC solution, and the ClinPhone® RTSM technologies, the eClinical Suite supports real-time data interchange and enables diverse applications to work synergistically. For more information about Perceptive's eClinical Suite, visit www.perceptive.com/Solutions/eClinical-Suite.html.

* Note: Perceptive's Randomization and Trial Supply Management (RTSM) solutions incorporate functionality that is often referenced as Interactive Voice and Web Response Systems (IVRS/IWRS).

About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit www.perceptive.com.


About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has more than 9,130 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings, including the anticipated restructuring charge of approximately $30 million over the second and third quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 as filed with the SEC on November 6, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

 

About Almirall
Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercializes its own R&D and licensed drugs with the aim of improving people's health and wellbeing.   
 
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and other dermatology indications.
 
Almirall's products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 11 affiliates.

For further information please visit the website at: www.almirall.com.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.